SNaRIs, NaSSAs, and NaRIs: New agents for the treatment of depression

Lancet

Volumn 355, Issue 9207, 2000, Pages 911-918

  Kent, Justine M ^a  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIDEPRESSANT AGENT; MIRTAZAPINE; NEFAZODONE; NORADRENALIN UPTAKE INHIBITOR; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

DEPRESSION; NEUROTRANSMISSION; NORADRENERGIC SYSTEM; PRIORITY JOURNAL; REVIEW; SEROTONINERGIC SYSTEM;

EID: 0034635825     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(99)11381-3     Document Type: Review

References (80)

1. Anderson I.M. SSRIs versus tricyclic antidepressants in depressed inpatients. a meta-analysis of efficacy and tolerability Depress Anxiety. 7:1998;11-17.
2. Taylor D.P., Carter R.B., Eison A.S.et al. Pharmacology and neurochemistry of nefazodone, a novel antidepressant drug. J Clin Psychiatry. 56:1995;3-11.
3. Hyttel J. Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int Clin Psychopharmacol. 9:1994;19-26. (suppl 1).
4. Eison A.S., Eison M.S., Torrente J.R.et al. Nefozodone. preclinical pharmacology of a new antidepressant Psychopharmacol Bull. 26:1990;311-315.
5. Hall H., Ogren S.-O. Effects of antidepressant drugs on different receptors in the brain. Eur J Pharmacol. 70:1981;393-407.
6. Feighner J.P., Boyer W.F. Selective serotonin reuptake inhibitors: the clinical use of citalopram, fluoxetine, fluvoxamine, paroxetine and sertraline. Perspectives in psychiatry. Vol 1. 1993;Wiley, Chichester.
7. Wong EHF, Graveel CR, Smith MW. Pharmacological selectivity of reboxetine: a selective noradrenaline reuptake inhibitor (NARI). Proc Ann Meeting Am Coll Neuropsychopharmacol Hawaii, USA: Dec 1997.
8. de Boer T., Maura G., Raiteri M.et al. Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, mirtazapine and its enantiomers. Neuropharmacology. 27:1988;399-408.
9. Venlafaxine. USA package insert, Wyeth Ayerst, 3/99.
10. Nefazodone. USA package insert, Bristol Myers Squibb, 4/99.
11. Mirtazapine. USA package insert, Organon 7/98.
12. Reboxetine European package insert, Pharmacia & Upjohn, 12/97.
13. Bolden-Watson C., Richelson E. Blockade by newly developed antidepressant of biogenic amine uptake into rat brain synaptosomes. Life Sci. 52:1993;1023-1029.
14. Muth E.A., Haskins J.T., Moyer J.A.et al. Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. Biochem Pharmacol. 35:1986;4493-4497.
15. Klamerus K.J., Malone K., Rudoph R.L.et al. Introduction of a composite parameter to the pharmcokinetics of venlafaxine and its active O-desmethyl metabolite. J Clin Pharmacol. 32:1992;716-724.
16. Taylor D.P., Smith D.W., Hyslop D.K.et al. Receptor binding and atypical antidepressant drug discovery. O'Brien R.A. Receptor binding in drug research. 1986;151-165 Marcel Dekker, New York.
17. de Boer T. The pharmacological profile of mirtazapine. J Clin Psychiatry. 57:1996;19-25. (suppl 4).
18. de Boer T. The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission. Int Clin Psychopharmacol. 10:1995;19-23. (suppl 4).
19. Riva M., Brunello N., Rovescalli A.C.et al. Effect of reboxetine, a new antidepressant drug, on the central noradrenergic system. behaviouiral and biochemical studies J Drug Dev. 1:1989;243-253.
20. Guelfi J.D., White C., Hackett D.et al. Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia. J Clin Psychiatry. 56:1995;450-458.
21. Khan A., Fabre L.F., Rudolph R. Venlafaxine in depressed outpatients. Psychopharmacol Bull. 27:1991;141-144.
22. Mendels J., Johnston R., Mattes J.et al. Efficacy and safety of b.i.d. doses of venlafaxine in a dose-response study. Psychopharmacol Bull. 29:1993;169-174.
23. Schweizer E., Weise C., Clary C.et al. Placebo-controlled trial of venlafaxine for the treatment of major depression. J Clin Psychopharmacol. 11:1991;233-236.
24. Cunningham L.A. Once-daily extended release (XR) and venlafaxine immediate release in outpatients with major depression. Ann Clin Psychiatry. 14:1997;99-106.
25. Thase M.E. Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression. the Venlafaxine XR 209 Study Group J Clin Psychiatry. 58:1997;393-398.
26. Schweizer E., Feighner J., Mandos L.A.et al. Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. J Clin Psychiatry. 55:1994;104-108.
27. Clerc G.E., Ruimy P., Verdeau-Palles J. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. Int Clin Psychopharmacol. 9:1994;139-143.
28. Dierick M., Ravizza L., Realini R.et al. A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Prog Neuropsychopharmacol Biol Psychiatry. 20:1996;57-71.
29. Costa e Silva J. Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression. J Clin Psychiatry. 59:1998;352-357.
30. Mendlewicz J. Pharmacologic profile and efficacy of venlafaxine. Int Clin Psychopharmacol. 10:1995;5-13. (suppl 2).
31. Entsuah A.R., Rudolph R.L., Hackett D.et al. Efficacy of venlafaxine and placebo during long-term treatment of depression. a pooled analysis of relapse rates Int Clin Psychopharmacol. 11:1996;137-145.
32. Fontaine R., Ontiveros E., Elie R.et al. A double-blind comparison of nefazodone, imipramine, and placebo in major depression. J Clin Psychiatry. 55:1994;234-241.
33. Mendels J., Reimher F., Marcus R.N.et al. A double-blind, placebo-controlled trial of two dose ranges of nefazodone in the treatment of depressed outpatients. J Clin Psychiatry. 56:1995;30-36. (suppl 6).
34. Rickels K., Schweizer E., Clary C.et al. Nefazodone and imipramine in major depression. a placebo-controlled trial Br J Psychiatry. 164:1994;802-805.
35. Cohn C.K., Robinson D.S., Roberts D.L.et al. Responders to antidepressant drug treatment: a study comparing nefozodone, imipramine, and placebo in patients with major depression. J Clin Psychiatry. 57:1996;15-18. (suppl 2).
36. Feigner J.P., Pambakian R., Fowler R.C.et al. A comparison of nefazodone, imipramine, and placebo in patients with moderate to severe depression. Psychopharm Bull. 25:1989;219-221.
37. Baldwin D.S., Hawley C.J., Abed R.T.et al. A multicenter double-blind comparison of nefazodone and paroxetine in the treatment of outpatients with modrate-to-severe depression. J Clin Psychopharmacol. 57:1996;46-52. (suppl 2).
38. Feiger A., Kiev A., Shrivastava R.K.et al. Nefazodone versus sertraline in outpatients with major depression: focus on efficacy, tolerability, and effects on sexual function and satisfaction. J Clin Psychiatry. 57:1996;53-62. (suppl 2).
39. Gillin J.C., Rapaport M., Erman M.K.et al. A comparison of nefazodone and fluoxetine on mood and on objective, subjective, and clinician-rated measures of sleep in depressed patients. a double-blind, 8-week clinical trial J Clin Psychiatry. 58:1997;185-192.
40. Ansseau M., Darimont P., Lecoq A.et al. Controlled comparison of nefazodone and amitriptyline in major depressive inpatients. Psychopharmacology (Berl). 115:1994;254-260.
41. Rickels K., Robinson D.S., Schweizer E.et al. Nefazodone: aspects of efficacy. J Clin Psychiatry. 56:1995;43-46. (suppl 6).
42. Feighner J., Targum S.D., Bennett M.E.et al. A double-blind, placebo-controlled trial of nefazodone in the treatment of patients hospitalized for major depression. J Clin Psychiatry. 59:1998;246-253. (suppl 6).
43. Anton S.F., Robinson D.S., Roberts D.L.et al. Long-term treatment of depression with nefazodone. Psychopharmacol Bull. 30:1994;165-169.
44. Montgomery S.A. Efficacy of nefazodone in the treatment of depression. J Psychopharmacol. 10:1996;5-10. (suppl 1).
45. Feiger A.D., Bielski R.J., Bremner J.et al. Double-blind, placebo-substitution study of nefazodone in the prevention of release during continuation treatment of outpatients with major depression. Int Clin Psychopharmacol. 14:1999;19-28.
46. Kasper S. Clinical efficacy of mirtazapine: a review of meta-analysis of pooled data. Int Clin Psychopharmacol. 10:1995;25-35. (suppl 4).
47. Kasper S., Praschak-Rieder N., Tauscher J.et al. A risk-benefit assessment of mirtazapine in the treatment of depression. Drug Saf. 17:1997;251-264.
48. Fawcett J., Barkin R.L. Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression. J Affect Disord. 51:1998;267-285.
49. Claghorn J.L., Lesem M.D. A double-blind placebo-controlled study of Org 3770 in depressed outpatients. J Affect Disord. 34:1995;165-171.
50. Bremner J.D. A double-blind comparison of Org 3770 amitriptyline, and placebo in major depression. J Clin Psychiatry. 56:1995;519-525.
51. Smith W.T., Glaudin V., Panagides J.et al. Mirtzapine vs amitriptyline vs placebo in the treatment of major depression. Psychopharmacol Bull. 26:1990;191-196.
52. Richou H., Ruimy P., Charbaut J.et al. A multicentre double-blind, clomipramine-controlled efficacy and safety study of Org 3770. Hum Psychopharmacol. 10:1995;263-271.
53. Zikov M., Roes K.C.R., Pols A.G. Efficacy of Org 3770 (mirtazapine) vs amitriptyline in patients with major depressive disorder: a meta-analysis. Hum Psychopharmacol. 10:1995;S135-145. (suppl).
54. Zivkov M., de Jongh G.D. Org 3770 versus amitriptyline. a 6-week randomized double-blind multicenter trial in hospitalized depressed patients Hum Psychopharmacol. 10:1995;173-180.
55. Wheatley D.P., van Moffaert M., Timmerman L.et al. Mirtazapine. efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder J Clin Psychiatry. 59:1998;306-312.
56. Halikas J.A. Org 3770 (mirtazapine) versus trazodone: a placebo controlled trial in depressed elderly patients. Hum Psychopharmacol. 10:1995;S125-133. (suppl).
57. Hoyberg O.J., Maragakis B., Mullin J.et al. A double-blind, multicenter comparison of mirtazapine and amitriptyline in elderly depressed patients. Acta Psychiatr Scand. 93:1996;184-190.
58. Montgomery S.A., Reimitz P.E., Zivkov M. Mirtazapine versus amitriptyline in the long-term treatment of depression. a double-blind, placebo-controlled study Int Clin Psychopharmacol. 18:1998;63-73.
59. Burrows G.D., Maguire K.P., Norman T.R. Antidepressant efficacy and tolerability of the selective norepinephrine reuptake inhibitor reboxetine: a review. J Clin Psychiatry. 59:1998;4-7. (suppl 14).
60. Montgomery S.A. Reboxetine: additional benefits to the depressed patient. J Psychopharmacol. 11:1997;9-15. (suppl 4).
61. Massana J, Moller H-J. In severe depression, reboxetine is as effective as imipramine and more effective than fluoxetine. Proc Ann Meeting Am Psychiatric Assoc. Toronto, Canada: May 1998; 129 (NR 227 abstr).
62. Katona C., Bercoff E., Chiu E.et al. Reboxetine versus imipramine in the treatment of elderly patients with depressive disorders. a double-blind randomised trial J Affect Disord. 55:1999;203-213.
63. Dubini A., Bosc M., Polin V. Noradrenaline-selective antidepressant therapy: differential effects on social functioning. J Psychopharmacol. 11:1997;17-23. (suppl 4).
64. Versiani M., Mehilane L., Gaszner P., Arnaud-Castiglioni R. Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder. J Clin Psychiatry. 60:1999;400-406.
65. Robinson D.S., Roberts D.L., Smith J.M.et al. The safety profile of nefazodone. J Clin Psychiatry. 57:1996;31-38. (suppl 2).
66. Aranda-Michel J., Koehler A., Bejarano P.A.et al. Nefazodone-induced liver failure. report of three cases Ann Intern Med. 130:1999;285-288.
67. Mongomery S.A. Safety of mirtazapine: a review. Int Clin Psychopharmacol. 10:1995;37-45. (suppl 4).
68. Davis R., Wilde M.I. Mirtazapine. a review of its pharmacology and therapeutic potential in the management of major depression CNS Drugs. 5:1996;389-402.
69. Mucci M. Reboxetine: a review of antidepressant tolerability. J Psychopharmacol. 11:1997;33-37. (suppl 4).
70. Richelson E. Pharmacokinetic drug interactions of new antidepressants. a review of the effects on the metabolism of other drugs Mayo Clin Proc. 72:1997;835-847.
71. Owen J.R., Nemeroff C.B. New antidepressants and the cytochrome P450 system: focus on venlafaxine, nefazodone and mirtazapine. Depression Anxiety. 7:1998;24-32. (suppl 1).
72. Wienkers LC, Allievi C, Hauer MJ, et al. Cytochrome P450-mediated metabolism of the individual enantiomers of the antidepressant agent reboxetine in human liver microsomes (in press).
73. Ball S.E., Ahern D., Scatina J.et al. Venlafaxine. in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism: comparative studies with selected SSRIs, and effects on human hepatic CYP34A, CYP2C9 and CYP1A2 Br J Clin Pharmacol. 43:1997;619-626.
74. Davis R., Whittington R., Bryson H.M. Nefazodone. a review of its pharmacology and clinical efficacy in the management of major depressioin Drugs. 53:1997;608-636.
75. Kroboth P.D., Folan M.M., Lush R.M.et al. Coadministration of nefazodone and benzodiapines I. pharmacodynamic assessment J Clin Psychopharmacol. 15:1995;306-319.
76. Greene D.S., Salazar D.E., Dockens R.C.et al. Coadministration of nefazodone and benzodiazepines IV. a pharmacokinetic interaction study with lorazepam J Clin Psychopharmacol. 15:1995;409-416.
77. Kuitunen T. Drug and ethanol effects on the clinical test for drunkenness. single doses of ethanol, hypnotic drugs and antidepressant drugs Pharmacol Toxicol. 75:1994;91-98.
78. Sisten J.M.A., Zikov M. Mirtazpine: clinical profile. CNS Drugs. 4:1995;39-48. (suppl 1).
79. Herman B.D., Fleishaker J.C., Brown M.T. Ketoconazole inhibits the clearance of the enantiomers of the antidepressant reboxetine in humans. Clin Pharmacol Ther. 2000;. (in press).
80. Dostert P., Benedetti M.S., Poggesi I. Review of the pharmacokinetics and metabolism of reboxetine, a selective noradrenaline reuptake inhibitor. Eur Neuropsychopharmacol. 7:1997;23-35. (suppl 1).